Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection


FitzGerald, Richard, Dickinson, Laura ORCID: 0000-0001-5557-9396, Else, Laura, Fletcher, Thomas, Hale, Colin, Amara, Alieu ORCID: 0000-0002-1137-2948, Walker, Lauren ORCID: 0000-0002-3827-4387, Penchala, Sujan Dilly, Lyon, Rebecca, Shaw, Victoria ORCID: 0000-0002-0429-0186 et al (show 9 more authors) (2022) Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. CLINICAL INFECTIOUS DISEASES, 75 (1). E525-E528.

Access the full-text of this item by clicking on the Open Access link.
[img] Text
Pharmacokinetics of ß-d-N4-hydroxycytidine, the parent nucleoside of prodrug molnupiravir, in non-plasma compartments of pat.pdf - Author Accepted Manuscript
Download (342kB) | Preview

Abstract

ß-d-N4-hydroxycytidine (NHC), the parent nucleoside of molnupiravir, a COVID-19 antiviral, was quantified at SARS-CoV-2 transmission sites in 12 patients enrolled in AGILE Candidate-Specific Trial-2. Saliva, nasal, and tear NHC concentrations were 3%, 21%, and 22% that of plasma. Saliva and nasal NHC were significantly correlated with plasma (P < .0001). Clinical Trials Registration. NCT04746183.

Item Type: Article
Uncontrolled Keywords: COVID-19, molnupiravir, nonplasma, pharmacokinetics, SARS-CoV-2
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 16 May 2022 09:52
Last Modified: 18 Jan 2023 21:02
DOI: 10.1093/cid/ciac199
Open Access URL: https://academic.oup.com/cid/advance-article/doi/1...
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3154864
Dimensions
Altmetric
CORE (COnnecting REpositories)